Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab + HMCT in R/R CD19+ ALL
NCT03751709Phase 1Completed
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Feb 2020
- Primary completion
- Mar 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in acute lymphoblastic leukemia (ALL), sponsored by Cedars-Sinai Medical Center. Primary endpoint: Incidence of Dose Limiting Toxicities at 6 months. Started Feb 2020; status: completed.
02
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03751709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03751709.